FY2024 EPS Estimates for Liquidia Lifted by Lifesci Capital

Liquidia Co. (NASDAQ:LQDA) – Research analysts at Lifesci Capital boosted their FY2024 EPS estimates for Liquidia in a research note issued to investors on Wednesday, November 13th. Lifesci Capital analyst C. Jubinville now expects that the company will post earnings of ($1.48) per share for the year, up from their prior estimate of ($1.57). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($1.55) per share. Lifesci Capital also issued estimates for Liquidia’s Q4 2024 earnings at ($0.36) EPS.

Several other research firms have also recently commented on LQDA. HC Wainwright reiterated a “buy” rating and set a $29.00 target price on shares of Liquidia in a research note on Thursday. BTIG Research cut their target price on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, August 19th. Scotiabank began coverage on shares of Liquidia in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 target price for the company. Bank of America cut their target price on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, August 20th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $19.00 target price on shares of Liquidia in a research note on Thursday. One analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $24.00.

Liquidia Trading Down 1.8 %

Shares of Liquidia stock opened at $9.84 on Monday. The stock has a market capitalization of $832.86 million, a price-to-earnings ratio of -6.04 and a beta of 0.21. Liquidia has a 1-year low of $6.10 and a 1-year high of $16.99. The firm has a fifty day simple moving average of $10.52 and a 200-day simple moving average of $11.48.

Insider Buying and Selling at Liquidia

In other news, CFO Michael Kaseta sold 3,892 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $43,240.12. Following the sale, the chief financial officer now owns 311,076 shares of the company’s stock, valued at approximately $3,456,054.36. This represents a 1.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Caligan Partners Lp bought 150,000 shares of the stock in a transaction dated Friday, August 30th. The stock was purchased at an average cost of $9.51 per share, for a total transaction of $1,426,500.00. Following the acquisition, the director now owns 6,994,997 shares in the company, valued at $66,522,421.47. The trade was a 2.19 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold 21,551 shares of company stock valued at $236,021 in the last 90 days. 30.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Liquidia

Large investors have recently made changes to their positions in the company. Quest Partners LLC bought a new stake in Liquidia during the 2nd quarter worth about $27,000. Hilltop National Bank bought a new stake in Liquidia during the 2nd quarter worth about $33,000. Deuterium Capital Management LLC bought a new stake in Liquidia during the 2nd quarter worth about $120,000. Clear Harbor Asset Management LLC bought a new stake in Liquidia during the 3rd quarter worth about $100,000. Finally, Signaturefd LLC grew its holdings in Liquidia by 38,400.0% during the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock worth $100,000 after acquiring an additional 9,984 shares during the last quarter. Institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).